Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) generates frequent news as an oncology company focused on full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics®. Its disclosures highlight clinical progress, regulatory designations, corporate transactions and collaboration updates that are relevant to investors and observers of the biotechnology sector.
A central theme in recent Merus news is the development of petosemtamab (MCLA-158), a Biclonics® antibody targeting EGFR and LGR5. Company announcements describe interim data from phase 2 trials in metastatic colorectal cancer, including combinations with FOLFOX and FOLFIRI and monotherapy in later-line settings, as well as data in recurrent or metastatic head and neck squamous cell carcinoma. News releases detail response rates, safety observations and presentations at major scientific meetings such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the American Society of Clinical Oncology Annual Meeting.
Another important news stream concerns regulatory and strategic milestones. Merus has reported that the U.S. FDA granted Breakthrough Therapy Designation to petosemtamab in two head and neck cancer settings, and it has provided updates on phase 3 registration trials in first-line and later-line recurrent or metastatic HNSCC. In parallel, the company issues regular financial and business updates, including quarterly results, capital raises, and details on research collaborations with partners such as Incyte, Eli Lilly, Gilead, Ono and Biohaven.
Recent company announcements also cover the agreed acquisition of Merus by Genmab A/S through a cash tender offer and subsequent back-end transactions. Joint releases and 8-K filings describe the tender offer terms, acceptance levels, change of control and plans for a subsequent offering period. For users following MRUS news, this page offers a consolidated view of clinical, regulatory, financial and corporate developments, including the transition of Merus into an indirect wholly owned subsidiary of Genmab.
Merus N.V. announced financial results for Q1 2024 and provided updates on its innovative oncology treatments. Petosemtamab in combination with pembrolizumab showed promising results in HNSCC, Zeno BLA accepted for priority review by FDA for NRG1+ NSCLC and PDAC. Cash runway expected into 2027. Collaboration with Incyte, Eli Lilly, and Gilead progressing well. Financially, a decrease in collaboration revenue but an increase in R&D and G&A expenses reported.
Merus N.V. announced that the U.S. FDA has accepted a priority review for the Biologics License Application of the bispecific antibody zenocutuzumab (Zeno) for NRG1+ NSCLC and PDAC. If approved, Zeno will be the first targeted therapy for NRG1+ cancer, offering a potential breakthrough in treatment options for patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.